TBPM.Q Stock Overview
A biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tetra Bio-Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.75% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TBPM.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | -99.8% | 14.2% | 32.3% |
Return vs Industry: TBPM.Q underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: TBPM.Q underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| TBPM.Q volatility | |
|---|---|
| TBPM.Q Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TBPM.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine TBPM.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Guy Chamberland | www.tetrabiopharma.com |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Inc. Fundamentals Summary
| TBPM.Q fundamental statistics | |
|---|---|
| Market cap | US$515.00 |
| Earnings (TTM) | -US$27.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TBPM.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBPM.Q income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$39.02m |
| Earnings | -CA$39.02m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did TBPM.Q perform over the long term?
See historical performance and comparison